Successful long-term treatment with linezolid for disseminated infection with multiresistant Nocardia farcinica

Infection

Volumn 36, Issue 4, 2008, Pages 389-391

  Rivero, A ^a   Garcia Lazaro M ^a   Perez Camacho I ^a   Natera, C ^a   Del Carmen Almodovar, M ^a   Camacho, A ^a   Torre Cisneros, J ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CLINDAMYCIN; COTRIMOXAZOLE; CYCLOSPORIN; DEFLAZACORT; DOXYCYCLINE; IMIPENEM; LINEZOLID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; VANCOMYCIN;

ADULT; BLOOD TOXICITY; BRAIN ABSCESS; CASE REPORT; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; LABORATORY TEST; LETTER; LONG TERM CARE; MACULOPAPULAR RASH; MALE; NOCARDIA FARCINICA; NOCARDIOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCEPTION DEAFNESS; PHYSICAL EXAMINATION; PLEURA EFFUSION; POLYNEUROPATHY; THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACETAMIDES; ADULT; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MICROBIAL SENSITIVITY TESTS; NOCARDIA; NOCARDIA INFECTIONS; OXAZOLIDINONES; PLEURAL EFFUSION; TIME FACTORS; TREATMENT OUTCOME;

EID: 50649100879     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-008-7236-7     Document Type: Letter

References (22)

1. Peleg AY, Husain S, Qureshi ZA, Silveira FP, Sarumi M, Shutt KA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007; 44: 1307-1314.
2. Munoz J, Mirelis B, Aragon LM, Gutierrez N, Sanchez F, Espanol M, et al. Clinical and microbiological features of nocardiosis 1997-2003. J Med Microbiol 2007; 56: 545-550.
3. Biehle JR, Cavallieri JR, Saubolle MA, Getsinger LJ: Comparative evaluation of the Etest for susceptibility testing of Nocardia species. Diagn Microbiol Infect Dis 1994; 19: 101-110.
4. Ambaye AP, Kohner C, Wollan PC, Roberts KL, Roberts GD, Cockerill FR: Comparison of agar dilution, broth microdilution, disk diffusion, E-test, and BACTEC radiometric methods for antimicrobial susceptibility testing of Nocardia asteroides complex. J Clin Microbiol 1997; 35: 847-852.
5. Dorman SE, Guide SV, Conville PS, DeCarlo ES, Malech HL, Gallin JI: Nocardia infection in chronic granulomatous disease. Clin Infect Dis 2002; 35: 390-394.
6. Parmentier L, Salmon-Ceron D, Boiron P, Paul G, Guez T, Dupont B, et al. Pneumopathy and kidney abscess due to Nocardia farcinica in an HIV-infected patient. AIDS 1992; 6: 891-893.
7. Nampoory MRN, Khan ZU, Johny KV, Nessim J, Gupta RK, Al-Muzairai I: Nocardiosis in renal transplant recipients in Kuwait. Nephrol Dial Transplant 1996; 11: 1134-1138.
8. Minamoto GY, Sordillo EM: Disseminated nocardiosis in a patient with AIDS: diagnosis by blood and cerebrospinal fluid cultures. Clin Infect Dis 1998; 26: 242-243.
9. Miksits K, Stoltenburg G, Neumayer HH, Spiegel H, Schaal KP, Cervos-Navarro J, et al. Disseminated infection of the central nervous system caused by Nocardia farcinica. Nephrol Dial Transplant 1991; 6: 209-214.
10. Lewis DE, Ebden P, Wooster SL, Rees J, Harrison GA: Multi-system infection with Nocardia farcinica-therapy with linezolid and minocycline. J Infect 2003; 46: 199-202.
11. Moylett EH, Pacheco SE, Brown-Elliott BA, Perry TR, Buescher S, Birmingham MC: Clinical experience with linezolid for the treatment of Nocardia infection. Clin Infect Dis 2003; 36: 313-318.
12. Soriano A, Gomez J, Gomez L, Azanza JR, Perez R, Romero F, et al. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur J Clin Microbiol Infect Dis 2007; 26: 353-356.
13. Senneville E, Legout L, Valette M, Yazdanpanah Y, Beltrand E, Caillaux M, Migaud H, Mouton Y: Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006; 28: 1155-1163.
14. Fortun J, Martin-Davila P, Navas E, Perez-Elias MJ, Cobo J, Tato M, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005; 56: 180-185.
15. Senneville E, Legout L, Valette M, Yazdanpanah Y, Giraud F, Beltrand E, Obert G, Dubreuil L, Migaud H, Mouton Y: Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother 2004; 54: 798-802.
16. Plachouras D, Giannitsioti E, Athanassia S, Kontopidou F, Papadopoulos A, Kanellakopoulou K, Giamarellou H: No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment. Clin Infect Dis 2006; 43: e89-e91.
17. Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ: Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother 2003; 37: 517-520.
18. Lewis KE, Ebden P, Wooster SL, Rees J, Harrison GA: Multi-system infection with Nocardia farcinica-therapy with linezolid and minocycline. J Infect 2003; 46: 199-202.
19. Spellberg B, Yoo T, Bayer AS: Reversal of linezolid-associated cytopaenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother 2004; 54: 832-835.
20. McKinley SH, Foroozan R: Optic neuropathy associated with linezolid treatment. J Neuroophthalmol 2005; 25: 18-21.
21. Bressler AM, Zimmer SM, Gilmore JL, Somani J: Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004; 4: 528-531.
22. Ferry T, Ponceau B, Simon M, Issartel B, Petiot P, Boibieux A: Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases. Infection 2005; 33: 151-154.